Skip to main content
Clinical Trials/NCT06628752
NCT06628752RecruitingNot Applicable

Deep Brain Stimulation for the Treatment of Severe Obsessive-compulsive Disorder

Umeå University1 site in 1 country26 target enrollmentStarted: September 11, 2018Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
26
Locations
1
Primary Endpoint
Yale-Brown Obsessive Compulsive Scale, Y-BOCS

Study Overview

Brief Summary

The goal of this clinical trial is to evaluate the treatment method of deep brain stimulation (DBS) in patients diagnosed with severe and treatment-resistant obsessive-compulsive disorder (OCD). DBS will be administered into the brain area of the bed nucleus of stria terminalis (BNST).

The main research questions are:

  • Does active DBS in BNST reduce OCD symptoms (primary outcome)?
  • Does active DBS in BNST reduce anxiety or depressive symptoms and improve the level of daily function?

The participants will be randomized to active or sham DBS in the BNST for six months and we will measure the outcomes before DBS surgery, and six months post-surgery. After the randomization phase, the participants will enter an open-label phase and receive continuous DBS in BNST. Yearly follow-ups will be conducted. The outcomes will be measured through interviews using validated psychometric scales.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Masking Description

The participant and the outcome assessor are blinded to whether the participant receives active or sham stimulation.

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •OCD diagnosed according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV).
  • •The patients should have received at least 16 sessions of cognitive behavioral therapy, tried three different serotonergic antidepressants in adequate doses for three months, and one serotonergic antidepressant in combination with a neuroleptic drug.
  • •Severe OCD symptoms: YBOCS ≥ 25 points.
  • •Substantial incapacity because of his/her symptoms.
  • •Duration of symptoms: 5 years minimum.
  • •Understand the consequences of participation in the study and give informed written consent.

Exclusion Criteria

  • •Not being able to understand the consequences of the treatment.
  • •Diagnosed with intellectual disability according to DSM-IV.
  • •Not meeting the requirements for the neurosurgery procedure.

Arms & Interventions

Active stimulation

Active Comparator

Deep brain stimulation - active stimulation

Intervention: Deep brain stimulation (Device)

Sham stimulation

Sham Comparator

Deep brain stimulation - no stimulation

Intervention: Deep brain stimulation (Device)

Outcomes

Primary Outcomes

Yale-Brown Obsessive Compulsive Scale, Y-BOCS

Time Frame: From enrollment to the end of treatment after 6 months.

Validated psychometric scale that measures symptoms of OCD.

Secondary Outcomes

  • Hamilton Anxiety Scale, HAS(From enrollment to the end of treatment after 6 months.)
  • Hamilton Depression scale, HAMD(From enrollment to the end of treatment after 6 months.)
  • Montgomery Asberg Depression Rating Scale, MADRS(From enrollment to the end of treatment after 6 months.)
  • Global Assessment of Functioning, GAF(From enrollment to the end of treatment after 6 months.)
  • Clinical Global Impression rating scale, CGI(From enrollment to the end of treatment after 6 months.)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials